<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0002725'>Systemic lupus erythematosus</z:hpo> is a multisystemic disease of unknown etiology with diverse clinical symptoms depending on the organ affected </plain></SENT>
<SENT sid="1" pm="."><plain>Plasma of affected patients contains a specific <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> called <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>It is an antibody which belongs to the class of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> which bind to phospolipid-binding proteins, molecules of natural coagulation inhibitors, thus increasing the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002725'>Systemic lupus erythematosus</z:hpo> commonly affects the skin, joints, serosa, hematopoietic tissue, kidneys and the <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="4" pm="."><plain>Pulmonary symptoms may manifest as <z:hpo ids='HP_0002102'>pleurisy</z:hpo>, <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0006530'>interstitial pulmonary disease</z:hpo>, but pulmonary <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> is the most common pulmonary manifestation </plain></SENT>
<SENT sid="5" pm="."><plain>CASE REPORT: This is a case report of a young female patient who has been suffering from <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> for twenty years </plain></SENT>
<SENT sid="6" pm="."><plain>She was treated for <z:hpo ids='HP_0002638'>superficial thrombophlebitis</z:hpo> for several times </plain></SENT>
<SENT sid="7" pm="."><plain>She was admitted to our hospital a year before, when she developed pulmonary <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> following <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> of the right leg, although at that time she was treated by oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>She was discharged from hospital with vena cava filter placement and further <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment </plain></SENT>
<SENT sid="9" pm="."><plain>In a one year period she was hospitalized again due to relapse pulmonary of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>DISCUSSION: Thrombotic complications in systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> are more frequent in patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Prevention of thrombotic complications by <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> agents in patients who already developed thrombotic manifestations is considered necessary </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: <z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> treatment should be, for preventive reasons, introduced in <z:hpo ids='HP_0000001'>all</z:hpo> patients with a <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> and with <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> factor, even if they haven't developed a thrombotic attack and they should undergo prothrombin time measurements and INR: 3-4 </plain></SENT>
</text></document>